Navigation Links
BioVex Raises $40 Million in First Close of Series F Financing
Date:3/30/2009

WOBURN, Mass., March 30 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today it has raised $40 million in the first close of a series F private financing.

The placement was led by Forbion Capital Partners, who were joined by other existing investors including Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners.

Philip Astley-Sparke, President & CEO for BioVex Inc said:

"Following the unprecedented number of durable complete remissions generated with our lead cancer product, OncoVEX GM-CSF in a Phase II study in metastatic melanoma, the funds will be used to commence a pivotal Phase III study. The Board is currently examining a number of options to raise a further $20 million to fund preparations for a BLA filing following the generation of Phase III data in 2010."

The Phase III study design agreed with the FDA under a Special Protocol Assessment (SPA) follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable Stage IIIc and Stage IV disease using OncoVEX GM-CSF as monotherapy. Stage IIIb patients will also be eligible. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX GM-CSF and 120 patients receive control. BioVex plans to begin enrolling patients for the Phase III study in the second quarter of 2009.

'/>"/>
SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. BioVex to Present at the UBS Global Life Sciences Conference
2. BioVex Closes Second Round of Series E Financing
3. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
4. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
5. Moodys Raises Boston Scientifics Rating Outlook to Stable
6. GlycoVaxyn AG Raises CHF 25 Million in Financing Led by Edmond de Rothschild Investment Partners
7. Eiger BioPharmaceuticals Raises $7.1 Million A Round
8. NanoBio Corporation Raises $12 Million in Series B Financing
9. Divergence Raises $11.8 Million in Series C Financing
10. Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009.
11. AMERIGROUP Praises Expansion of State Childrens Health Insurance Program (SCHIP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... transplant rejection occurs when the transplant recipient,s immune system ... it. It was previously thought that T cells, the ... by molecules known as chemokines in order to migrate ... Journal of Clinical Investigation , Fadi Lakkis and ... demonstrate that chemokine stimulation of T cells is not ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in ... association’s recent annual meeting drew praise from community leaders ... who called the action “a huge step forward … ... European innovation.” , The Board of Stakeholders voted to ... PPP at its 29 April meeting in Brussels, which ...
(Date:5/17/2013)... May 17, 2013  Cellular Biomedicine Group (OTCQB: ... enrollment of the total projected enrollment required for ... and preliminary efficacy of the medical technology haMPC ... Osteoarthritis (KOA). To date the trial has had ... The Phase I open label clinical research trial ...
(Date:5/17/2013)...  Insero Health, Inc., a company developing natural compounds ... neurological disorders, is today reporting top-line results from a ... patients with drug-resistant epilepsy.  The data are being presented ... meeting by Dr. Steven Schachter , ... Advisory Board.  In this study, INS001 appeared safe and ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2
... SANTA CLARA, Calif., Oct. 10 Finesse Solutions, ... life science process,applications, is pleased to announce improvements ... and transmitters even easier. The E-Store,can be found ... can now easily purchase bioprocess sensors and accessories,on-line, ...
... ... People, INDIANAPOLIS, Oct. ... it has made the list of Top 20,biopharmaceutical employers, according to the ... in the biotechnology, biopharmaceutical, pharmaceutical and,related industries. This year Lilly ranks number ...
... Technologies announced,today that David E. Kandzari, MD, ... System" during the Drug-Eluting Stent Summit at ... on October 13, 2008. The MiStent(TM), a ... polymer coating that,delivers the potential therapeutic benefits ...
Cached Biology Technology:Lilly Recognized as One of the World's Top Biopharmaceutical Employers 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... shown a gene involved in neurodegenerative disease also plays ... circadian clock. , In a study of the ... Ataxin-2, keeps the clock responsible for sleeping and waking ... of the fruit fly,s sleep-wake cycle is disturbed, making ... fly. , The discovery is particularly interesting because ...
(Date:5/16/2013)... The relationship between the heritable risk for schizophrenia ... Schizophrenia is commonly associated with cognitive impairments that ... reduced IQ may be linked to the risk ... may precede the onset of schizophrenia symptoms. Also, ... of people diagnosed with schizophrenia. , In a ...
Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 2Genetic risk for schizophrenia is connected to reduced IQ 2
... Blacksburg, Va. Researchers have unveiled the evolutionary ... three species of Agrobacterium. A comprehensive comparison of ... of other bacteria suggests a general model for ... Agrobacteria are members of the Rhizobiaceae family, which ...
... and a fast bite spelled doom for bony fishes during ... a new study to be published March 31, 2009, in ... Today, those same features characterize large predatory bony ... decline and at risk of extinction themselves, said Matt Friedman, ...
... developed at the University of California, Davis to treat ... human clinical trials to evaluate its efficacy. ... is "a first-in-class drug which may treat a suite ... Hammock, who with UC Berkeley cell biologist Sarjeet Gill ...
Cached Biology News:Evolutionary origin of bacterial chromosomes revealed 2Study unravels why certain fishes went extinct 65 million years ago 2Study unravels why certain fishes went extinct 65 million years ago 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 2UC Davis bench-to-bedside research: Promising treatment in clinical trials 3UC Davis bench-to-bedside research: Promising treatment in clinical trials 4UC Davis bench-to-bedside research: Promising treatment in clinical trials 5
...
... to quantitate double-stranded DNA (dsDNA) in solution, even ... this kit, DNA is stained with Hoechst 33258 ... or other fluorometer. The kit quantitates dsDNA in ... 5 micrograms per ml and contains Hoechst 33258, ...
... of colony stimulating factors for assays of ... blood and fetal liver. Suitable for ... and CFU-GEMM when added to methylcellulose at ... of erythropoietin. Will also support growth ...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Biology Products: